Russia and Cuba sign agreement to expand research on innovative cancer Drug

Russia and Cuba to begin research on new cancer drug.

On Wednesday the representative of BioCubaFarma in Russia and the national company Alphanil signed a co-development agreement to expand the research of an innovative drug against cancer. The signing took place in Moscow.

The scientific-technical attaché of the Cuban Group of Biotechnological and Pharmaceutical Industries (BioCubaFarma), Adolfo Castillo, told Prensa Latina that the Center of Molecular Immunology of the Caribbean island will be the leading institution of the project on the Cuban side.

In this regard, he added that the agreement responds to the objectives of his organization to establish alliances with Russian developers in the sector to achieve joint products that can be registered and applied for the benefit of this country and other nations in the Eurasian region.

For his part, the general director of the Russian company Alphanil, Dmitri Chelovsky, pointed out that this innovation comes after the success of a similar one, but dedicated to the treatment of Parkinson’s disease.

He pointed out that the new product is in the middle of the preclinical stage and is being developed in Cuba at the Center for Research and Development of Medicines (CIDEM) and on the Russian side with Neyros.

This article was published by Cubadebate and has been translated by our staff.